Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
PD-L1 expression appeared to be highly positive in both lung tumor cells and, particularly MDSCs.
|
30771521 |
2019 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
|
31235866 |
2019 |
Lung Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Compared with 212 EGFR wild-type lung cancers, outcomes with programmed cell death 1 or programmed death-ligand 1 (PD-(L)1) blockade were worse in patients with lung tumors harboring alterations in exon 19 of EGFR (EGFRΔ19) but similar for EGFRL858R lung tumors.
|
31086949 |
2019 |
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
This study aimed to investigate the role of EZH2 in PD-L1 expression and in the progression of lung tumors.
|
31331645 |
2019 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.
|
30318514 |
2018 |
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Epidermal growth factor receptor (EGFR) activation was reported to upregulate programmed death-ligand 1 (PD-L1) expression in lung cancer cells and subsequently contribute to immune escape, indicating its critical role in EGFR-driven lung tumors.
|
30766753 |
2018 |
Lung Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Image analysis accurately enumerated CD8+ TILs in PD-L1+ regions of lung tumors using the dual assay and also measured elongate CD8+ lymphocytes which constituted a fraction of overall TILs.
|
29510739 |
2018 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Furthermore, 0.3% GTE in drinking water reduced the average number of tumors per mouse from 4.1 ± 0.5 to 2.6 ± 0.4 and the percentage of PD-L1 positive cells from 9.6% to 2.9%, a decrease of 70%, in lung tumors of A/J mice given a single intraperitoneal injection of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
|
30126206 |
2018 |
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Statistically significant differences in M1 and M2 macrophage infiltration were observed in AAs (<i>P</i> < 0.05); however, <i>PD-L1, PD-L2</i> expression was similar between both.<b>Conclusions:</b> Comparative transcriptomic profiling revealed clear differences in lung tumor biology between AAs and EAs.
|
29196495 |
2017 |
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Increased PD-L1 expression and IL-6 secretion characterize human lung tumor-derived perivascular-like cells that promote vascular leakage in a perfusable microvasculature model.
|
28878242 |
2017 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Anti-PD-1/PD-L1 therapy inhibited CMT167 orthotopic lung tumors by 95%.
|
28819064 |
2017 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
CTD_human |
Autophagy inhibition upregulates CD4+ tumor infiltrating lymphocyte expression via miR-155 regulation and TRAIL activation.
|
27692344 |
2016 |
Lung Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
We found that lung tumors containing ALK rearrangements induced an immunosuppressive microenvironment, regulating the expression of PD-L1 on the surface of lung tumor cells.
|
26419961 |
2015 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We show that autochthonous EGFR-driven lung tumors inhibit antitumor immunity by activating the PD-1/PD-L1 pathway to suppress T-cell function and increase levels of proinflammatory cytokines.
|
24078774 |
2013 |
Lung Neoplasms
|
0.400 |
Biomarker
|
group |
LHGDN |
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression.
|
15297412 |
2004 |